Z08.0

Encounter for follow-up examination after completion of treatment for malignant neoplasm

Z08.0 represents an essential component of comprehensive cancer care, specifically designated for encounters where a patient undergoes a follow-up examination after the completion of active treatment for a malignant neoplasm. This code is critical for tracking and managing the post-treatment phase, focusing on long-term surveillance rather than ongoing therapy. 'Completion of treatment' typically implies that all planned curative or definitive therapeutic interventions, such as surgery, chemotherapy, or radiation therapy, have concluded. It does not preclude the management of late-stage side effects or the development of new, unrelated conditions. The primary objectives of such follow-up encounters are multifaceted: to detect early signs of cancer recurrence, to identify new primary malignancies, to monitor for and manage long-term or late-onset adverse effects of cancer treatment, and to provide psychological and supportive care to enhance the patient's quality of life. These examinations involve a tailored approach, considering the type and stage of the original cancer, the treatments received, and the patient's overall health status. Surveillance protocols often include physical examinations, laboratory tests (e.g., tumor markers), and imaging studies (e.g., CT, MRI, PET scans) performed at scheduled intervals, which typically become less frequent over time. The use of Z08.0 allows for accurate billing and data collection for these crucial encounters, differentiating them from encounters for ongoing treatment (e.g., Z51.x codes for chemotherapy/radiotherapy encounters) or diagnosis of an initial malignancy. This code underscores the ongoing need for medical oversight in survivorship care, emphasizing proactive monitoring to ensure optimal long-term outcomes for cancer survivors.

Clinical Symptoms

  • Unexplained persistent fatigue
  • Unintentional weight loss or changes in appetite
  • New or worsening pain, especially localized and persistent
  • Unusual lumps or masses
  • Palpable lymphadenopathy
  • Changes in skin lesions, moles, or appearance
  • Persistent cough, hoarseness, or difficulty swallowing
  • Changes in bowel or bladder habits
  • Blood in stool or urine
  • Neurological changes such as headaches, seizures, or vision disturbances
  • Unusual bleeding or bruising
  • Swelling in extremities
  • Numbness, tingling, or weakness
  • Signs of organ dysfunction related to prior treatment, such as cardiac toxicity, pulmonary fibrosis, or kidney impairment
  • Psychological distress, anxiety, or depression related to cancer survivorship

Common Causes

  • The inherent risk of cancer recurrence, where residual microscopic disease may regrow or spread years after initial treatment
  • The possibility of developing a second primary cancer, which can be influenced by genetic predispositions, environmental factors, or prior cancer treatments themselves (e.g., chemotherapy, radiation therapy)
  • The potential for long-term and late-onset adverse effects of cancer therapies, including damage to various organ systems (e.g., cardiac, pulmonary, renal, neurological, endocrine), secondary malignancies induced by treatment, chronic pain syndromes, fatigue, and psychosocial challenges
  • The need for psychosocial support and health promotion tailored to cancer survivors, addressing issues like fear of recurrence, body image concerns, sexual dysfunction, and lifestyle modifications to optimize long-term health
  • Guideline-driven surveillance protocols designed to improve patient outcomes through early detection and intervention

Documentation & Coding Tips

Distinguish between active treatment and follow-up surveillance. Use Z08 only when the primary treatment for a malignancy—such as surgery, radiotherapy, or chemotherapy—has been completed and the patient is being monitored for recurrence.

Example: Patient presents for 6-month oncology follow-up. Status post-bilateral mastectomy and adjuvant chemotherapy completed 14 months ago for Stage II Invasive Ductal Carcinoma. No active complaints of fatigue or bone pain. Plan: CT Chest/Abdomen/Pelvis for surveillance and labs including CBC and CMP. ICD-10: Z08, Z85.3.

Billing Focus: Documentation must explicitly state that the treatment is complete to justify Z08 as the first-listed code, followed by the specific history of malignancy Z85 code.

Specify the exact type and site of the malignancy being monitored by using secondary Personal History codes from the Z85 category. This ensures clinical granularity for recurrence risk assessment.

Example: Follow-up for history of malignant neoplasm of the sigmoid colon, status post-resection and 12 cycles of FOLFOX completed January 2024. Today is a 1-year surveillance visit. CEA level ordered. No evidence of recurrence on physical exam. ICD-10: Z08, Z85.038.

Billing Focus: Laterality and specific anatomical sites for the historical malignancy should be documented to support the medical necessity of specific imaging orders.

Document the absence of symptoms or clinical signs of recurrence to confirm the encounter is for surveillance (follow-up) rather than an acute diagnostic workup for a suspected new primary or relapse.

Example: Patient seen for follow-up of history of malignant neoplasm of the lung. Completed stereotactic body radiation therapy 2 years ago. Patient is asymptomatic with no cough, hemoptysis, or weight loss. Imaging scheduled to confirm continued remission. ICD-10: Z08, Z85.118.

Billing Focus: Clearly documenting a lack of symptoms supports the use of Z08 instead of symptom-based R-codes, which could trigger different medical necessity criteria for payers.

When maintenance therapy is ongoing (e.g., Tamoxifen or Lupron), clarify if the provider considers the primary treatment phase finished. Z08 is used for the check-up, while Z79 codes should be used for long-term drug use.

Example: Follow-up status post-lumpectomy for ER-positive breast cancer. Finished radiation last year. Currently on Tamoxifen for 5-year maintenance. Visit is for annual oncology check-up. No masses palpated. ICD-10: Z08, Z85.3, Z79.811.

Billing Focus: Combining Z08 with Z79.811 (long-term use of aromatase inhibitors or selective estrogen receptor modulators) correctly captures the management of a patient in the surveillance phase who is also receiving preventive treatment.

Ensure the documentation supports the medical decision-making complexity, especially when reviewing prior multi-modality treatment records or complex imaging (PET, MRI) during the follow-up.

Example: Surveillance visit for history of melanoma of the back. Wide local excision and sentinel node biopsy completed 3 years ago. Reviewed recent PET scan results and pathology from 2021. Full skin exam performed. No suspicious lesions. ICD-10: Z08, Z85.820.

Billing Focus: The review of external records and prior diagnostic results should be documented to support the MDM level for E/M coding (e.g., 99214).

Relevant CPT Codes

Related Diagnoses

Hierarchy